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ABSTRACT 
A RP-HPLC methods were developed and validated for simultaneous estimation of Phenylephrine HCl (PE), 
Doxylamine  Succinate (DOX) and Dextromethorphan HBr (DEX). The separation was achieved on a 
Princestone ODS C18 (250mm X 4.6 mm i.d., 10 μm particle size) with an Isocratic system of Phosphate Buffer 
(10 mM) : Methanol : Acetonitrile (pH 4) in the ratio of 70:25:5 v/v/v. The retention time for PE, DOX and 
DEX was obtained as 5.125 min, 10.419 min and 2.661 min respectively with a flow rate of 1.0 ml/min at 
detection wavelength 215 nm. The linearity of the proposed method was investigated in the range of 25 -125 
μg/ml, 31.25 - 156.25 µg/ml and 50 - 250 μg/ml for PE, DOX and DEX respectively. The developed method 
was validated as per ICH guideline and found to be satisfactory.  
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INTRODUCTION 
Phenylephrine (3-[(1R)-1-hydroxy-2-(methyl amino) ethyl] phenol) Fig 1 is a selective α1-adrenergic receptor 
agonist  used primarily as a decongestant, as an agent to dilate the pupil, and to increase blood pressure. 
Phenylephrine is marketed as a substitute for the decongestant pseudoephedrine, though clinical studies differ 
regarding its effectiveness in this role. Doxylamine (dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine) 
Fig 2 is a first generation antihistamine. It can be used by itself as a short-term sedative and in combination with 
other drugs to provide night-time allergy and cold relief. Doxylamine is also used in combination with the 
analgesics paracetamol (acetaminophen) and codeine as an analgesic/calmative preparation, and is prescribed in 
combination with vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.Dextromethorphan 
((1R,9R,10R)-4-methoxy-17-methyl-17-azatetracyclo [7.5.3.0^{1,10}.0^{2,7} ]heptadeca-2,4,6-triene) 
(DXM or DM) Fig 3 is an antitussive (cough suppressant) drug. It is one of the active ingredients in many over-
the-counter cold and cough medicines, 
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Literature  review  reveals  that numbers of individual analytical methods available for estimation of PEl
[17], 
DOX and DEX
[18] 
MATERIALS AND METHODS 
individually reported. And also reveals that numbers of analytical methods available for 
estimation of PE, DOX, and DEX in their combined dosage forms with other drugs reported but no analytical 
method was for reported combination of drugs. 
Gift sample of PE, DOX, and DEX was  procured  from  Gujarat  Liqui  Pharma  Caps  Pvt.  Ltd.  Waghodiya 
GIDC, Vadodara. Methanol, Acetonitrile, KH2PO7, 
 
Ortho-phosphoric acid, Triethylamine HPLC grade were 
procured from RANKEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Phenylephrine 
 
 
Figure 3 Doxylamine 
 
 
Figure 1 Dextromethorphan 
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OPTIMIZED HPLC CONDITION  Observation 
Column  Princestone ODS C18 (250mm X 4.6 mm i.d., 10 μm particle size) 
Mobile Phase  Phosphate Buffer (10 mM): Methanol: Acetonitrile (70:25:5, pH-
4.0) 
Detection Wavelength  215 nm 
Flow Rate  1 ml/min 
Injection Volume  40 μL 
Retention Time 
Phenylephrine HCl: - 5.125 min 
Doxylamine Succinate:-10.419 min 
Dextromethorphan HBr: - 2.661 min 
Selection of detection wavelength  
PE, DOX, and DEX therefore prepared in Distilled Water. These drug solutions were than scanned in the UV 
region of 200-400 nm and the overlain spectrums were recorded and final wavelength 215 nm is selected for 
detection of the drugs.  
Preparation of mobile phase 
A mixture of 70 ml of 10 mM Phosphate Buffer (pH 2.5), 25 ml of methanol and 5 ml of acetonitrile  is taken 
and  final pH of  the solution  is  made  4 with  Triethylamine.  This mobile phase filtered through 0.75 μm filter 
paper, Sonicated for 15 minutes to degas the mixture and used as mobile phase. 
Preparation of standard stock solution 
A 10 mg of standard use PE, 12.5 mg of standard DOX and 20 mg of standard DEX was weighed and transferred 
to a 25 ml volumetric flask and dissolved in 25 ml mobile phase. The flask was shaken and volume was made up 
to the mark with mobile phase to give a solution containing 250 μg/ml PE, 312.5 μg/ml DOX and 500 μg/ml 
DEX.  
Preparation of Calibration  curve 
Appropriate volume of aliquots from standard stock solutions were transferred to same volumetric flasks of 10 
ml capacity. The volume was adjusted to the mark with mobile phase give a solution containing 25, 50, 
75,100,125 μg/ml PE, 31.25, 62.50, 93.75, 156.25 μg/ml DOX and 50, 100, 150, 200, 250 μg/ml DEX. The 
mixed standard solution was chromatographed for 10 minutes using mobile phase at a flow rate of 1.0 ml/min. 
The graphs were plotted for peak area vs. concentration for both the drugs. Fig 4, 5, 6, concentrations  in  the 
range of 25-125 μg/ml, 31.25-156.25 μg/ml and 50-250 μg/ml for PE, DOX, and DEX respectively. 
Sample preparation 
For estimation of PE, DOX, and DEX mixture was prepared. Mixture equivalent to 10 mg PE, 12.5 mg DOX and 
20 mg DEX was accurately weighed and transferred to volumetric flask of 25 ml capacity. 10 ml of mobile phase 
was transferred to volumetric flask and Sonicated for 15 min. The flask was shaken and volume was made up to 
the mark with mobile phase. The above solution was filtered through whatman filter paper (0.75μ). Volume was 
made up to the mark using mobile phase to give a solution containing 250 μg/ml PE and 312.5 μg/ml DOX and 
500 μg/ml DEX (solution A). From the solution A, 1 ml was transferred to volumetric flask of 10 ml capacity and 
volume was and 50 g/ml DOX. This solution used made up to the mark using mobile phase to give a solution 
containing 25 μg/ml PE and 31.25 μg/ml DOX for estimation of drugs.  
Precision 
Repeatability 
Six  replicates  of  standard  mixture  solution  having  50  μg/ml  PE,  62.50 μg/ml DOX and 100 μg/ml DEX 
were prepared and chromatograms were recorded and RSD was calculated.  
Intraday precision 
Standard solutions containing 25, 75 and 150 μg/ml PE and 31.25, 93.75 and 156.25 μg/ml DOX and 50, 150, 
250 μg/ml DEX were analyzed three times on the same day. Chromatogram of each sample was taken. SD and 
RSD were calculated. 
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Standard solutions containing 25, 75 and 150 μg/ml PE and 31.25, 93.75 and 156.25 μg/ml DOX and 50, 150, 
250 μg/ml DEX were  analyzed  on  three  different  days.  Chromatogram  of  each sample was taken. SD and 
RSD were calculated. 
Robustness 
Robustness study was performed by altered chromatographic conditions Wavelength (± 1nm), flow rate (± 0.2 
ml/min), Variation in pH (± 0.2). 
Duplicate injections of a standard mixture solution having PE (50 µg/ml), DOX  (62.5  µg/ml)  and  DEX 
(100  µg/ml)  were analyzed  as  per  the  procedure  in  each  altered  condition  and  chromatograms  were 
recorded.  %RSD  of  PE,  DOX  and  DEX  was  calculated.  If  any  particular  change  in  method  caused 
failure  of  system suitability that change was identified as a critical parameter and it was highlighted in the 
method of analysis 
RESULT & DISCUSSION 
Fig. 4 Chromatogram of Developed RP-HPLC Method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linearity  was  performed  on  synthetic  mixture  of  Phenylephrine HCl, Doxylamine  Succinate and 
Dextromethorphan HBr. At different concentration in mixture at 215 nm at flow rate of 1 ml/min was used for 
making calibration curve 
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Analyte  Concentration (µg/ml)  Average Peak area          (n=3) 
PE 
25  1695832 
50  3339237 
75  4783227 
100  6398557 
125  7962198 
DOX 
31.5  1168252 
62.50  2594612 
93.75  3726211 
125.00  5278426 
156.25  6721561 
DEX 
50  242746 
100  379742 
150  543955 
200  726798 
250  888206 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Graph of Calibration curve for PE 
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Fig. 6 Graph of Calibration curve for DOX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Graph of Calibration curve for DEX 
TABLE 3. % ASSAY OF PE, DOX, AND DEX 
 
 
 
Drug 
Concentration in 
synthetic mix as per 
market formulation 
(mg) 
Concentration 
taken for % Assay 
(µg/ml) 
Average 
Peak  
Area of 
sample 
Concentration 
found from mix.  % Assay 
PE  5  50  3328870  50.840  101.68 
DOX  6.5  62.5  2518848  62.500  100.00 
DEX  10  100  387703  98.630  98.63 
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Concentration of Pre analyzed sample of PE: 50.932 μg/ml, DOX: 61.365 μg/ml and DEX: 99.325 μg/ml 
TABLE 5: INTRADAY PRECISION DATA FOR PE, DEX AND DOX (N=3) 
 
Standard drug 
Target Concentration 
(µg/ml) 
Mean Peak 
area of 
samples (n=3) 
Mean of Found 
Concentration 
(μg/ml) 
SD 
PE 
25  1689756  24.557  0.199 
75  4795598  74.356  0.080 
125  7965438  125.180  0.299 
DOX 
31.25  1146032  31.393  0.602 
93.75  3731122  89.961  0.292 
156.25  6648768  156.089  0.904 
DEX 
50  233490  51.463  0.200 
150  550683  148.286  0.383 
250  882970  250.463  0.994 
 
 
 
 
 
 
 
 
Level 
of 
Spiking 
(%) 
 
Amount of 
Drug Spiked 
(µg/ml) 
Total 
Conc. Of 
Drug 
(µg/ml) 
Peak  
Area of 
Sample 
(n=3) 
Amount of 
Drug found 
(µg/ml) 
(n=3) 
Amount Of 
Drug 
recovered 
(µg/ml) 
Recovery 
Mean ± SD 
(%,n=3) 
PE 
50%  25  75  4884695  75.786  24.852  99.409 ± 0.845 
100%  50  100  6406346  100.183  49.250  98.500 ± 0.508 
150%  75  125  7946718  124.881  73.949  98.598 ± 0.442 
DOX 
50%  31.25  93.75  3842714  92.503  31.137  99.683 ± 0.845 
100%  62.50  125.00  5270907  125.017  63.651  101.600±0.241 
150%  93.75  156.25  6644601  155.995  94.629  100.938±0.149 
DEX 
50%  50  150  553302  149.087  49.764  99.523 ±0.384 
100%  100  200  718811  199.516  100.184  100.190±0.113 
150%  150  250  884219  250.098  150.773  100.515±1.004 
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TABLE 6: ROBUSTNESS DATA FOR PE, DEX AND DOX 
 
Parameters 
(n=3) 
Variation 
Average peak area 
(n=3) 
% RSD 
PE  DOX  DEX  PE  DOX  DEX 
Flow rate 
 
0.9  3334740  2492976  388844  0.451  0.241  0.098 
1.1  3338197  2523284  390332  0.062  0.240  0.353 
Wave length 
214  3299688  2539439  382628  0.689  0.752  0.209 
216  3334685  2592028  393239  0.592  0.274  0.478 
pH 
3.8  3320539  2478817  378459  0.215  0.710  0.396 
4.2  3375227  2532118  389294  0.688  0.672  0.144 
CONCLUSION 
A simple, specific, accurate and precise RP-HPLC method has been developed and validated for simultaneous 
estimation of PE, DOX and DEX in its synthetic mixture. PE, DOX and DEX were estimated on Princestone 
C18 column using Phosphate Buffer (10mM): Methanol:  Acetonitrile (pH 4) (70:25:5 v/v) as  mobile phase 
and detection was carried out at 215 nm. 
The linearity range was found to be 25-125 µg/ml of Phenylephrine HCl, 31.25-156.25 µg/ml of  Doxylamine 
Succinate and 50-250 µg/ml. The co-relation coefficient was found to be 0.999, 0.998 and 0.998 for PE, DOX 
and DEX respectively. The assay value for PE, DOX and DEX was found  to  be  101.68%,  100.01,  and 
98.63%  respectively.  The  present  method  was validated as per the ICH guideline so it can be adopted for its 
routine analysis.  
The developed method can be utilized for simultaneous estimation of PE, DOX and DEX. 
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